Journal ArticleDOI
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Reads0
Chats0
About:
This article is published in Yearbook of Neurology and Neurosurgery.The article was published on 2010-01-01. It has received 613 citations till now.read more
Citations
More filters
Journal ArticleDOI
3D Slicer as an image computing platform for the Quantitative Imaging Network.
Andriy Fedorov,Reinhard Beichel,Jayashree Kalpathy-Cramer,Julien Finet,Jean-Christophe Fillion-Robin,Sonia Pujol,Christian Bauer,Dominique Jennings,Fiona M. Fennessy,Milan Sonka,John M. Buatti,Stephen R. Aylward,James V. Miller,Steve Pieper,Ron Kikinis +14 more
TL;DR: An overview of 3D Slicer is presented as a platform for prototyping, development and evaluation of image analysis tools for clinical research applications and the utility of the platform in the scope of QIN is illustrated.
Journal ArticleDOI
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
Olivier Chinot,Wolfgang Wick,Warren P. Mason,Roger Henriksson,Frank Saran,Ryo Nishikawa,Antoine F. Carpentier,Khê Hoang-Xuan,Petr Kavan,Dana Cernea,Alba A. Brandes,Magalie Hilton,Lauren E. Abrey,Timothy F. Cloughesy +13 more
TL;DR: The addition of bevacizumab to radiotherapy-temozolomide did not improve survival in patients with glioblastoma, and the glucocorticoid requirement was lower.
Journal ArticleDOI
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Christine E. Brown,Darya Alizadeh,Renate Starr,Weng L,Wagner,Araceli Naranjo,Ostberg,Melvin Blanchard,Kilpatrick J,Simpson J,Kurien A,Saul J. Priceman,Xiuli Wang,Harshbarger Tl,Massimo D'Apuzzo,Ressler Ja,Michael C. Jensen,Michael E. Barish,Chen M,Jana Portnow,Stephen J. Forman,Behnam Badie +21 more
TL;DR: Recurrent multifocal glioblastoma patients received chimeric antigen receptor (CAR)-engineered T cells targeting the tumor-associated antigen interleukin-13 receptor alpha 2 (IL13Rα2) and regression of all intracranial and spinal tumors was observed, along with corresponding increases in levels of cytokines and immune cells in the cerebrospinal fluid.
Journal ArticleDOI
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
Derin B. Keskin,Annabelle J. Anandappa,Jing Sun,Itay Tirosh,Nathan Mathewson,Shuqiang Li,Giacomo Oliveira,Anita Giobbie-Hurder,Kristen Felt,Evisa Gjini,Sachet A. Shukla,Zhuting Hu,Letitia Li,Phuong M. Le,Rosa Lundbye Allesøe,Rosa Lundbye Allesøe,Alyssa R. Richman,Monika S. Kowalczyk,Sara Abdelrahman,Jack Geduldig,Sarah Charbonneau,Kristine Pelton,J. Bryan Iorgulescu,Liudmila Elagina,Wandi Zhang,Oriol Olive,Christine McCluskey,Lars Rønn Olsen,Jonathan Stevens,William J. Lane,Andres M. Salazar,Heather Daley,Patrick Y. Wen,E. Antonio Chiocca,Maegan Harden,Niall J. Lennon,Stacey Gabriel,Gad Getz,Eric S. Lander,Aviv Regev,Jerome Ritz,Donna Neuberg,Scott J. Rodig,Keith L. Ligon,Mario L. Suvà,Kai W. Wucherpfennig,Nir Hacohen,Edward F. Fritsch,Kenneth J. Livak,Patrick A. Ott,Catherine J. Wu,David A. Reardon +51 more
TL;DR: It is demonstrated that a strategy that uses multi-epitope, personalized neoantigen vaccination, which has previously been tested in patients with high-risk melanoma, is feasible for tumours such as glioblastoma, which typically have a relatively low mutation load and an immunologically ‘cold’ tumour microenvironment.
Journal ArticleDOI
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
Roger Stupp,Roger Stupp,Monika E. Hegi,Thierry Gorlia,Sara Erridge,James Perry,Yong-Kil Hong,Kenneth Aldape,Benoit Lhermitte,Torsten Pietsch,Danica Grujicic,Joachim P. Steinbach,Wolfgang Wick,Rafal Tarnawski,Do-Hyun Nam,Peter Hau,Astrid Weyerbrock,Martin J B Taphoorn,Chiung-Chyi Shen,Nalini Rao,László Thurzó,Ulrich Herrlinger,Tejpal Gupta,Rolf-Dieter Kortmann,Krystyna Adamska,Catherine McBain,Alba A. Brandes,Joerg C. Tonn,Oliver Schnell,Thomas Wiegel,Chae-Yong Kim,Louis B. Nabors,David A. Reardon,Martin J. van den Bent,Christine Hicking,Andriy Markivskyy,Martin Picard,Michael Weller +37 more
TL;DR: This multicentre, open-label, phase 3 study investigated the efficacy of cilengitide in patients from 146 study sites in 25 countries and found none of the predefined clinical subgroups showed a benefit.
References
More filters
Journal ArticleDOI
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen,David R. Macdonald,David A. Reardon,Timothy F. Cloughesy,A. Gregory Sorensen,Evanthia Galanis,John DeGroot,Wolfgang Wick,Mark R. Gilbert,Andrew B. Lassman,Christina Tsien,Tom Mikkelsen,Eric T. Wong,Marc C. Chamberlain,Roger Stupp,Kathleen R. Lamborn,Michael A. Vogelbaum,Martin J. van den Bent,Susan M. Chang +18 more
TL;DR: The recognition that contrast enhancement is nonspecific and may not always be a true surrogate of tumor response and the need to account for the nonenhancing component of the tumor mandate that new criteria be developed and validated to permit accurate assessment of the efficacy of novel therapies.
Journal ArticleDOI
Response criteria for phase II studies of supratentorial malignant glioma.
TL;DR: This work suggests "new" response criteria for phase II studies of supratentorial malignant glioma and favor rigorous criteria similar to those in medical oncology, with important modifications, to minimize misinterpretations of response.
Related Papers (5)
Updated response assessment criteria for high-grade glioma: beyond the MacDonald criteria.
The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria.
Lakshmi Nayak,Lisa M. DeAngelis,Alba A. Brandes,David M. Peereboom,Evanthia Galanis,Nan Lin,Riccardo Soffietti,David R. Macdonald,Marc C. Chamberlain,James Perry,Kurt A. Jaeckle,Minesh P. Mehta,Roger Stupp,Alona Muzikansky,Elena Pentsova,Timothy F. Cloughesy,Fabio M. Iwamoto,Joerg C. Tonn,Michael A. Vogelbaum,Patrick Y. Wen,Martin J. van den Bent,David A. Reardon +21 more